VALN Valneva SE
Valneva SE (VALN) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $0.17 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +30.8% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Valneva SE
Valneva SE is a specialty vaccine company. It is focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva SE is based in Saint-Herblain, France.
Sector
Healthcare
Industry
Drug Manufacturers/Other